New radionuclide combination therapy safe and effective in metastatic prostate cancer patients

A novel nuclear medicine combination therapy has been proven safe and effective in men with heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC). The therapy, which combines the newly FDA-approved radionuclide therapy ¹⁷⁷Lu-PSMA-617 with a radiosensitizer known as idronoxil (NOX66), reduced prostate specific antigen (PSA) levels by more than 50 percent in a significant number of patients, resulting in a median overall survival of 19.7 months. This research was published in the April issue of The Journal of Nuclear Medicine.

mCRPC is a lethal disease, with a five-year survival rate of only 30 percent. Treatment options are limited, and treatment resistance occurs frequently. Combination therapies, however, may overcome these resistance mechanisms and improve patient outcomes.

“NOX66 has shown potential as a radiation sensitizer in prostate cancer. Our study was developed to determine if combining NOX66 with ¹⁷⁷Lu-PSMA-617 could improve treatment response with minimal increase in toxicity for mCRPC patients,” said Louise Emmett, MD, MBChB, FRACP, director of theranostics and nuclear medicine at St. Vincent’s Hospital in Sydney, Australia.

The study included 56 men with progressive mCRPC who were previously treated with chemotherapy and novel androgen signaling inhibitors (ASI), a type of hormonal therapy. Patients received up to six doses of ¹⁷⁷Lu-PSMA-617 in combination with varying doses of NOX66. After a median follow-up of 21.8 months, 86 percent of patients saw a decline in PSA levels, and nearly two-thirds of them had a PSA level decline of more that 50 percent.

Researchers also analyzed clinical, blood-based, and molecular imaging markers as potential predictors of treatment response. PSMA tumor volume at baseline measured by molecular imaging was the strongest predictor of treatment response and overall survival; the study found that men with higher tumor volumes responded poorly to treatment. Duration of treatment with ASI (more than 12 months) was associated with improved overall survival.

Emmett noted that these results point to two issues: “First, we need to ensure that men receive treatment earlier, before they have high-volume disease, and second, we need to explore why men with high-volume disease respond to treatment poorly,” she said. “Do we need to personalize radionuclide dose based on disease volume to get better treatment responses in men with high-volume disease? Further research is needed. It is clear, however, that trials like this help us explore how to safely prolong treatment responses and help men live longer, better lives.”

This study was made available online in July 2021.

Visit the JNM website for the latest research, and follow our new Twitter and Facebook pages @JournalofNucMed or follow us on LinkedIn.

The authors of “¹⁷⁷Lutetium-PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castration-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial” include Sarennya Pathmanandavel, Department of Theranostics and Nuclear Medicine, St. Vincent’s Hospital, Sydney, Australia, The Kinghorn Cancer Centre, St. Vincent’s Hospital, Sydney, Australia, and Garvan Institute of Medical Research, Sydney, Australia; Megan Crumbaker and Andrew O. Yam, The Kinghorn Cancer Centre, St. Vincent’s Hospital, Sydney, Australia, and Garvan Institute of Medical Research, Sydney, Australia, and St. Vincent’s Clinical School, University of New South Wales, Sydney, Australia; Andrew Nguyen, Department of Theranostics and Nuclear Medicine, St. Vincent’s Hospital, Sydney, Australia; Christopher Rofe, The Kinghorn Cancer Centre, St. Vincent’s Hospital, Sydney, Australia; Elizabeth Hovey, Nelune Comprehensive Cancer Centre, Prince of Wales Hospital, Sydney, Australia, and Faculty of Medicine, University of New South Wales, Sydney, Australia; Craig Gedye, Department of Medical Oncology, Calvary Mater Hospital, Newcastle, Australia, and Hunter Medical Research Institute, New Lamberton Heights; Newcastle, Australia; Edmond M. Kwan, Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia, and Department of Medical Oncology, Monash Health, Melbourne, Australia; Christine Hauser, Peter MacCallum Cancer Centre, Melbourne, Australia, and Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia; Arun A. Azad and Peter Eu, Peter MacCallum Cancer Centre, Melbourne, Australia; Andrew J. Martin, NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia; Anthony M. Joshua, The Kinghorn Cancer Centre, St. Vincent’s Hospital, Sydney, Australia, Garvan Institute of Medical Research, Sydney, Australia, St. Vincent’s Clinical School, University of New South Wales, Sydney, Australia, and Faculty of Medicine, University of New South Wales, Sydney, Australia; and Louise Emmett, Department of Theranostics and Nuclear Medicine, St. Vincent’s Hospital, Sydney, Australia, Garvan Institute of Medical Research, Sydney, Australia, St. Vincent’s Clinical School, University of New South Wales, Sydney, Australia, and Faculty of Medicine, University of New South Wales, Sydney, Australia

###

Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or [email protected].

About JNM and the Society of Nuclear Medicine and Molecular Imaging

The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed more than 13 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.

JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit www.snmmi.org.